BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.4M Compounds and 9.6K Targets. Of those, 1.5M data for 718K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

18 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate.EBI
Bayer Research Center
Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach.EBI
Bayer Research Center
Indanylacetic acids as PPAR-delta activator insulin sensitizers.EBI
Bayer Research Center
SAR of a novel 'Anthranilamide Like' series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancer.EBI
Bayer Research Center
Substituted indanylacetic acids as PPAR-alpha-gamma activators.EBI
Bayer Research Center
4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 2. SAR.EBI
Bayer Research Center
Substituted aminobenzimidazole pyrimidines as cyclin-dependent kinase inhibitors.EBI
Bayer Research Center
In vitro SAR of (5-(2H)-isoxazolonyl) ureas, potent inhibitors of hormone-sensitive lipase.EBI
Bayer Research Center
Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent.EBI
Bayer Research Center
Integration of optimized substituent patterns to produce highly potent 4-aryl-pyridine glucagon receptor antagonists.EBI
Bayer Research Center
Solid-phase synthesis and investigation of benzofurans as selective estrogen receptor modulators.EBI
Bayer Research Center
Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor.EBI
Bayer Research Center
Optimization of the 4-aryl group of 4-aryl-pyridine glucagon antagonists: development of an efficient, alternative synthesis.EBI
Bayer Research Center
Discovery of 5-hydroxyalkyl-4-phenylpyridines as a new class of glucagon receptor antagonists.EBI
Bayer Research Center
Discovery and parallel synthesis of a new class of cathepsin K inhibitors.EBI
Bayer Research Center
p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas.EBI
Bayer Research Center
1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors.EBI
Bayer Research Center
Discovery of a new class of p38 kinase inhibitors.EBI
Bayer Research Center